Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation
with the following ranked order: CYP3A4 > CYP2D6. Co-administration of ritonavir and medicinal
products primarily metabolised by CYP3A may result in increased plasma concentrations of the other
medicinal product, which could increase or prolong its therapeutic and adverse effects. For selected
9
medicinal products (e.g. alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease over
time. Ritonavir also has a high affinity for P-glycoprotein and may inhibit this transporter. The
inhibitory effect of ritonavir (with or without other protease inhibitors) on P-gp activity may decrease
over time (e.g. digoxin and fexofenadine-see table “Ritonavir effects on non-antiretroviral medicinal
products” below). Ritonavir may induce glucuronidation and oxidation by CYP1A2, CYP2C8,
CYP2C9 and CYP2C19 thereby increasing the biotransformation of some medicinal products
metabolised by these pathways, and may result in decreased systemic exposure to such medicinal
products, which could decease or shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Alprazolam 1, single dose 200 q12h, 2 days ↑ 2.5 fold ↔
500 q12h, 10 ↓ 12% ↓ 16%
days
Alprazolam metabolism was inhibited following the introduction of ritonavir. After
ritonavir use for 10 days, no inhibitory effect of ritonavir was observed. Caution is
warranted during the first several days when alprazolam is co-administered with
ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer, before
induction of alprazolam metabolism develops.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation
with the following ranked order: CYP3A4 > CYP2D6. Co-administration of ritonavir and medicinal
products primarily metabolised by CYP3A may result in increased plasma concentrations of the other
medicinal product, which could increase or prolong its therapeutic and adverse effects. For selected
medicinal products (e.g. alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease over
time. Ritonavir also has a high affinity for P-glycoprotein and may inhibit this transporter. The
inhibitory effect of ritonavir (with or without other protease inhibitors) on P-gp activity may decrease
over time (e.g. digoxin and fexofenadine-see table “Ritonavir effects on non-antiretroviral medicinal
products” below). Ritonavir may induce glucuronidation and oxidation by CYP1A2, CYP2C8,
CYP2C9 and CYP2C19 thereby increasing the biotransformation of some medicinal products
metabolised by these pathways, and may result in decreased systemic exposure to such medicinal
products, which could decease or shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
54
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co-administered Medicinal Dose of Effect on Co- Effect on Co-
Products (mg) NORVIR administered administered
(mg) Medicinal Medicinal
Products Products Cmax
AUC
Alprazolam 1, single dose 200 q12h, ↑ 2.5 fold ↔
2 days
500 q12h, ↓ 12% ↓ 16%
10 days
Alprazolam metabolism was inhibited following the introduction of ritonavir. After
ritonavir use for 10 days, no inhibitory effect of ritonavir was observed. Caution is
warranted during the first several days when alprazolam is co-administered with ritonavir
dosed as an antiretroviral agent or as a pharmacokinetic enhancer, before induction of
alprazolam metabolism develops.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage a055fde61c7c39dbb335e73d79277cfac8acc6c4a5efc9a317467dbcaa70ce48 · Zeichen 54690–56372 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.